1. GPCR/G Protein
  2. Prostaglandin Receptor

Iloprost (Synonyms: Ciloprost; ZK 36374)

Cat. No.: HY-A0096 Purity: 99.83%
Handling Instructions

Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2.

For research use only. We do not sell to patients.
Iloprost Chemical Structure

Iloprost Chemical Structure

CAS No. : 78919-13-8

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 333 In-stock
1 mg USD 108 In-stock
2 mg USD 180 In-stock
5 mg USD 420 In-stock
10 mg USD 660 In-stock
25 mg USD 1140 In-stock
50 mg USD 1920 In-stock
100 mg USD 3120 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Iloprost (ZK 36374) is a synthetic analogue of prostacyclin PGI2. Target: Iloprost is a stable prostacyclin analog commonly employed in the treatment of peripheral vascular disease and also indicated in the treatment of patients affected by systemic sclerosis (SSc) in the presence of severe Raynaud's phenomenon (RP). [1] Iloprost dilates systemic and pulmonary arterial vascularbeds. Iloprost also affects platelet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unknown. The two diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S isomer substantially more potent than the 4R isomer.[2] Iloprost is a stable carbacyclin derivative of prostacyclin, was studied during electrically-induced coronary artery thrombosis in the open chest anesthetized pig. Infusion of ZK 36374 (100 ng/kg/min, n = 6) had no effect on heart rate and cardiac output, but caused a 20% reduction in mean arterial blood pressure by peripheral vasodilation. In animals receiving solvent or no drug prior to thrombosis induction, the time to occlusive coronary artery thrombosis (TOT) was 30 +/- 2 minutes (mean +/- SEM, n = 17). Pretreatment with an i.v. infusion of ZK 36374 (100 ng/kg/min) prolonged TOT by 50% to 47 +/- 7 minutes (p less than 0.005, n = 6). This prolongation of TOT was not due to the lower blood pressure in the ZK 36374 group, as dihydralazine in a dose that lowered arterial blood pressure to the same extent had no effect on TOT (32 +/- 4 minutes, n = 4). The results indicate that ZK 36374 may be useful in delaying (or preventing) occlusive coronary artery thrombi. [3]

Clinical Trial
Molecular Weight







O=C(O)CCC/C=C1C[[email protected]@]2([H])C[[email protected]@H](O)[[email protected]](/C=C/[[email protected]@H](O)C(C)CC#CC)[[email protected]@]2([H])C\1

Pure form -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: